ENDRA Life Sciences approves 1:50 reverse stock split, increases authorized shares to 1B, appoints new Head of Finance

ENDRA Life Sciences Inc.

Senior Director of Finance Irina Pestrikova resigned Aug 7; Richard Jacroux appointed Head of Finance & principal financial officer on Aug 8.
Stockholders approved increase in authorized common shares from 80M to 1B; amendment filed Aug 8.
Board set reverse stock split ratio at 1-for-50, authorized by stockholders (range 1:20 to 1:50).
At Aug 6 annual meeting: all five director nominees elected; say-on-pay, warrant issuance, and auditor ratification passed.

item 5.02 item 5.03 item 5.07 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Richard Jacroux

Head of Finance

NDRA · ENDRA Life Sciences Inc.

Effective: 2024-08-08
Filed: August 9, 2024, 7:59 PM ET

On August 8, 2024, the Company’s Board of Directors (the “Board of Directors”) appointed Richard Jacroux as Head of Finance.

Departed

Irina Pestrikova

Senior Director, Finance

NDRA · ENDRA Life Sciences Inc.

Effective: 2024-08-07
Successor: Richard Jacroux
Filed: August 9, 2024, 7:59 PM ET

On August 5, 2024, Irina Pestrikova notified ENDRA Life Sciences Inc. (“ENDRA” or the “Company”) of her resignation as the Company’s Senior Director, Finance, effective August 7, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard Jacroux was appointed as Head of Finance at ENDRA Life Sciences Inc..

Action: appointed
Role: Head of Finance

Exact text from the filing

On August 8, 2024, the Company’s Board of Directors (the “Board of Directors”) appointed Richard Jacroux as Head of Finance.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Irina Pestrikova resigned as Senior Director, Finance at ENDRA Life Sciences Inc..

Action: resigned
Role: Senior Director, Finance

Exact text from the filing

On August 5, 2024, Irina Pestrikova notified ENDRA Life Sciences Inc. (“ENDRA” or the “Company”) of her resignation as the Company’s Senior Director, Finance, effective August 7, 2024.

View on SEC.gov

ENDRA Life Sciences Inc. filing history →

Source: SEC EDGAR

accession 0001654954-24-010213

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.